PLEXOVAL I study disrupted by the Covid-19 response
- PLEXOVAL is a world-first study using a cellfree, platelet-derived exosome product, manufactured using Exopharm's proprietary LEAP Technology, for wound healing
- COVID-19 has impacted the progress of Exopharm’s PLEXOVALI human trial, and will likely reduce recruitment numbers, neither Cohorts 1 and 2 will fully recruit, and the study report will be delayed
- Initial results from Cohort2 may be available in the coming months
- Planning is underway, for the follow-on study, using allogeneic(off-the-shelf) Plexaris
http://exopharm.com/wp-content/uploads/2020/04/72._20.04.01-Plexoval-update-Exopharm-Ltd-ASX_EX1.pdf
Buy Recommendation, page-68
Add TYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $19.60M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 117646 | 1.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.8¢ | 195662 | 2 |
View Market Depth
| Last trade - 10.09am 08/10/2024 (20 minute delay) ? |
| TYP (ASX) Chart |
Day chart unavailable